Full-Time

Staff Human Factors Engineer

Updated on 5/26/2026

HeartFlow

HeartFlow

501-1,000 employees

Non-invasive cardiac imaging to guide treatment

Compensation Overview

$190k - $250k/yr

+ Bonus + Equity

San Francisco, CA, USA

In Person

Travel up to 25% (domestic and international) may be required.

Category
QA & Testing (1)
Requirements
  • Education: BS/MS in Human Factors Engineering, Human-Computer Interaction, Biomedical Engineering, Cognitive/Experimental Psychology, or related discipline.
  • Experience: 7+ years of human factors engineering experience in medical devices, combination products, or regulated healthcare software (SaMD).
  • Regulatory Fluency: Deep working knowledge of IEC 62366-1, FDA Human Factors guidance (2016), ISO 14971, and EU MDR usability expectations.
  • Validation Track Record: Demonstrated ownership of summative human factors studies supporting successful regulatory submissions (e.g., 510(k), De Novo, PMA, or MDR technical documentation).
  • Methods: Proficiency in task analysis, use-FMEA/URRA, contextual inquiry, and moderated usability testing (in-person and remote).
  • Communication: Strong written and verbal communication skills; track record of authoring HFE reports that withstand regulatory review.
  • Travel: Available for up to 25% of travel, including both domestic and international trips (must be cleared for international travel).
Responsibilities
  • Establish and drive SaMD human factors and usability strategies in accordance with IEC 62366-1, FDA Human Factors guidance, and EU MDR expectations.
  • Execute and document usability engineering evaluations, including task analyses and human factors studies.
  • Author formative and summative usability study protocols.
  • Plan, coordinate, and moderate formative and summative usability studies.
  • Perform root cause analysis of use errors and aggregate data for presentations and formal reports.
  • Partner with external vendors as required to execute human factors evaluations (recruiting, study design, execution, analysis, & reporting)
  • Author and update usability risk analyses in collaboration with cross-functional stakeholders.
  • Partner with Quality teams to address potential complaints related to usability on-market products.
  • Work with design teams to create clinician-centric and compliant designs.
  • Assist in developing usability engineering processes for Quality system improvements.
  • Support inquiries, audits, and discussions with regulatory agencies.
Desired Qualifications
  • Clinical Domain: Experience with cardiovascular imaging, CT/MRI workflows, interventional cardiology, or AI/ML-enabled clinical decision support.
  • Simulation Experience: Experience running simulated-use studies in high-fidelity clinical or cath-lab simulation environments.
  • Adjacent Standards: Familiarity with IEC 60601-1-6, IEC 62304, ISO 13485, and 21 CFR 820 design controls.
  • Certification: CHFP or CPE certification.

HeartFlow provides a non-invasive cardiac test that helps doctors visualize a patient’s coronary arteries to diagnose and plan treatment for heart disease. It uses a proprietary set of analyses—FFRCT Analysis, RoadMap Analysis, Plaque Analysis, and HeartFlow Planner—to create a detailed, patient-specific visualization from imaging data, enabling clinicians to assess blood flow and plaque without surgery. This approach reduces the need for invasive procedures, lowers risk for patients, and can cut costs for healthcare providers. Compared with traditional methods, HeartFlow offers validated, FDA-cleared tools that integrate multiple analyses into one platform, giving physicians a clearer, data-driven basis for diagnosis and treatment decisions. The company’s goal is to improve cardiovascular care by making safer, more efficient diagnosis and treatment planning widely available in hospitals and clinics around the world.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue grew 41% to $52.6 million.
  • Plaque coverage reached 75% of covered lives by May 2026.
  • Case volume rose 67% to 67,443, showing stronger utilization.

What critics are saying

  • Abbott and GE HealthCare can bundle coronary workflow tools into existing contracts.
  • HeartFlow remains unprofitable, so execution misses force dilution or cash burn.
  • International reimbursement and procurement friction limits growth outside the United States.

What makes HeartFlow unique

  • HeartFlow combines CCTA anatomy with lesion-specific FFRCT physiology.
  • PCI Navigator extends the platform into pre-procedural stent planning.
  • FDA-cleared software is commercially deployed across five major markets.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at HeartFlow who can refer or advise you

Benefits

Remote Work Options

Stock Options

401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
HeartFlow soars 27% as firm targets 24-26% revenue growth in 2026

Heartflow Inc. surged 27% week-on-week following its strong 2025 performance and optimistic growth guidance. The medical technology company reported 2025 revenues of $176 million, up 40% from $125.8 million in 2024, with US revenues rising 41% to $160.6 million and international revenues climbing 26% to $15.4 million. The company remains unprofitable, posting a net loss of $116.79 million, 21% higher than the previous year. However, fourth-quarter net loss decreased 26% to $24.4 million. For 2026, Heartflow projects revenue growth of 24% to 26%, targeting between $218 million and $222 million. CEO John Farquhar said the guidance "reflects strong business fundamentals" and expressed high confidence in consistent execution.

Yahoo Finance
Mar 22nd, 2026
Capricorn Investment Group buys $48M stake in AI cardiac diagnostics firm HeartFlow

Capricorn Investment Group has purchased 1.7 million shares of HeartFlow, establishing a new position worth $48.18 million in the AI-powered cardiac diagnostics company, according to an SEC filing dated 17 February 2026. The stake represents 5.83% of Capricorn's reportable assets under management. HeartFlow offers AI-driven, non-invasive diagnostic solutions for coronary artery disease, generating revenue from healthcare providers and systems. The company went public in August 2025 and currently has a market capitalisation of $2.22 billion. As of 20 March 2026, HeartFlow shares traded at $26.30, down 10.7% year-to-date from a 52-week high of $41.22 reached last October. The company reported trailing twelve-month revenue of $161.88 million and a net loss of $125.37 million.

Yahoo Finance
Mar 17th, 2026
HeartFlow to report Q4 results with $46.5M revenue expected, analysts cut earnings forecast to -$2.11 per share

HeartFlow Inc is set to report Q4 2025 earnings on 18 March 2026. The consensus estimate projects revenue of $46.50 million and a loss of $0.27 per share. Full-year 2025 revenue is expected to reach $173.36 million, with a loss of $2.11 per share. Over the past 90 days, revenue estimates have increased slightly, whilst earnings estimates have declined. In Q3 2025, HeartFlow beat revenue expectations by 10.29% but missed earnings forecasts, posting a loss of $1.04 per share against an expected loss of $0.32 per share. The stock fell 13.43% following that release. Six analysts have set an average one-year price target of $38.50, suggesting an 83.51% upside from the current price of $20.98. The average brokerage recommendation is "Outperform".

Daily Political
Feb 3rd, 2026
HeartFlow's $317M IPO lock-up period ends tomorrow as analysts set $38.50 target

HeartFlow, a medical technology company developing non-invasive diagnostics for coronary artery disease, will see its lock-up period expire on 4th February. The company issued 16,666,667 shares in its August public offering at $19.00 per share, raising $316.7 million. Following the expiry, restrictions preventing company insiders and major shareholders from selling shares will be lifted. Shares traded at $28.78 on Tuesday, giving the company a market capitalisation of $2.45 billion. HeartFlow has received positive analyst coverage, with five buy ratings, two hold ratings and one sell rating. The consensus price target stands at $38.50. The company's technology uses computational modelling to analyse coronary CT angiography data, creating three-dimensional physiological models to identify coronary lesions without invasive procedures.

The Motley Fool
Nov 30th, 2025
HeartFlow Acquired for $65M by Billionaire

Tulsa-based Schusterman Interests acquired 1.9 million shares of HeartFlow, Inc. for $65 million, making it the fourth-largest holding in their portfolio. HeartFlow, an AI-driven heart diagnostics company, saw its shares rise 70% from its $19 IPO price in August. The acquisition reflects confidence in HeartFlow's technology and potential for revenue growth. As of September 30, HeartFlow represented 14.9% of Schusterman's 13F assets.